Recent research identifies exosomal lncRNAs in breast cancer as pivotal molecular switches that orchestrate the complex communication between malignant cells and the tumor microenvironment (TME). Specifically, these extracellular vesicles transport long non-coding RNAs to tumor-associated macrophages (TAMs), which then adapt to support tumor growth. This bidirectional signaling fosters an environment conducive to immune suppression, angiogenesis, and metabolic remodeling. Consequently, understanding these interactions is essential for developing next-generation oncology treatments.

Mechanisms of Exosomal lncRNAs in Breast Cancer Signaling

Tumor cells release exosomes containing specific lncRNAs that activate signaling pathways like STAT3 and TGF-β within macrophages. Furthermore, these molecules trigger Hippo/YAP and hypoxia-responsive signaling, effectively polarizing macrophages toward a tumor-supportive M2 phenotype. Conversely, macrophages reciprocate by secreting exosomal lncRNAs such as HISLA (hypoxia-inducible factor-1 alpha-stabilizing lncRNA). This specific cargo reinforces glycolytic adaptation and epithelial-mesenchymal transition (EMT) in recipient tumor cells. Therefore, the co-evolution of these two cell populations directly contributes to metastatic plasticity and therapeutic failure.

Clinical Potential and Future Directions

The stability of exosomal lncRNAs in breast cancer makes them excellent candidates for minimally invasive liquid biopsies. Identifying these markers in circulation could allow clinicians to monitor real-time changes in the TME and predict therapeutic resistance earlier than conventional imaging. However, researchers must still overcome significant hurdles, including vesicle heterogeneity and the need for standardized stoichiometry in clinical assays. Addressing these barriers will be a critical step toward integrating exosomal analysis into routine clinical practice.

Frequently Asked Questions

What role does HISLA play in breast cancer progression?

HISLA is a macrophage-derived exosomal lncRNA that stabilizes HIF-1α in breast cancer cells. This interaction promotes metabolic reprogramming, enhances the epithelial-mesenchymal transition, and increases resistance to chemotherapy.

How do exosomal lncRNAs influence the tumor microenvironment?

These RNAs act as messengers that remodel the TME by suppressing immune responses and promoting angiogenesis. They facilitate bidirectional communication between tumor cells and various stromal components, including macrophages and endothelial cells.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Javadian M et al. Exosomal lncRNAs as molecular switches driving macrophage-tumor co-evolution in breast cancer. Clin Exp Med. 2026 May 31. doi: 10.1007/s10238-026-02199-z. PMID: 42218707.


2. Dragomir M, et al. Exosomal lncRNAs as New Players in Cell-to-Cell Communication. Biomedical Journal. 2021.


3. Xie Y, et al. Exosomes in Breast Cancer: From Mechanisms to Clinical Applications. Frontiers in Oncology. 2022.